

Value Assessment & Pricing in France, the UK and Germany

Your speakers



Josie Godfrey
National Institute for Health
and Care Excellence (NICE)
London, GREAT BRITAIN

**Early dialogues,
health economics,
evaluation of orphans –
where are we heading
in Europe?**



Christian Hill
MAP BioPharma Limited,
Papworth Everard,
Cambridge, GREAT BRITAIN



Thomas Müller
Federal Joint Committee
(G-BA), Berlin, GERMANY



François Meyer MD
French National Authority
for Health – HAS,
Paris, FRANCE



Dr Alexander Natz
European Confederation
of Pharmaceutical
Entrepreneurs (EUCOPE),
Brussels, BELGIUM

Value Assessment & Pricing in France, the UK and Germany

Aims and objectives

Harmonisation of the drug value assessment in Europe still has far to go. The most promising projects to date are related to Multi-HTA early dialogues.

This meeting gives you an up-to-the-minute update on the harmonisation efforts as well as on national value assessment and pricing in France, Germany and the UK. What is the role of health economics in the different systems? How are orphan drugs, cancer drugs and drugs for chronic diseases assessed?

After having attended this meeting you will be aware of the current status of and the challenges for the national systems in the UK, France and Germany, and have a sound perspective on what you can expect from the European HTA cooperations.

Participants

This meeting addresses the needs of managing directors and co-workers in the pharmaceutical industry who are involved in market access and healthcare management.

Especially those who are responsible for the international business will benefit from this meeting.

Chairman



Dr Alexander Natz
European Confederation
of Pharmaceutical
Entrepreneurs (EUCOPE),
Brussels, BELGIUM

Secretary General

Your speakers



Josie Godfrey
National Institute for Health
and Care Excellence (NICE)
London, GREAT BRITAIN

Associate Director – Highly Specialised
Technologies



Christian Hill
MAP BioPharma Limited,
Papworth Everard,
Cambridge, GREAT BRITAIN

Director Market Access & Government
Affairs



François Meyer MD
French National Authority
for Health – HAS,
Paris, FRANCE

Advisor to the President of the HAS,
International Affairs



Thomas Müller
Federal Joint Committee
(G-BA), Berlin, GERMANY

Head of Pharmaceuticals Department

Your programme 9h00 - 17h00

9h00

Multi-HTA early dialogues

François Meyer

- Early dialogues with the HTA bodies
- Current challenges and successes of the SEED project – the current pilots
- The future of multi-HTA early dialogues
- Update on adaptive pathways

10h00

G-BA early dialogues in practice

Thomas Mueller

- Procedure, topics and experiences
- Participation of BfArM/PEI
- Challenges: consistency and indication-specific guidelines

10h30

Update on drug assessment by the French HAS

François Meyer

- Assessment of added clinical benefit ('ASMR') and the effect on pricing
- Introduction of health economics in the HTA process for new drugs
- Request for post-launch studies

11h15

Post-marketing study & evidence requirements

Thomas Müller

- National conditions
- Requirements for post-marketing studies, registries and real-world data
- Acceptance by the industry
- Harmonisation of the required additional data and study programmes?

12h00 Lunch

13h30

Drugs for rare diseases – the NICE perspective

Josie Godfrey

- Assessment of highly specialised technologies

14h30

Discussion round – orphans in Europe

Josie Godfrey, Thomas Müller, François Meyer

15h00 Coffee break

15h30

Pricing in the UK – How it relates to market access success

Christian Hill

- The pharmaceutical price regulation scheme (PPRS) – statutory regulations or voluntary scheme?
- Routes to market access in the UK
 - NICE and other UK HTAs
 - NHS England's commissioning policies
 - Commissioning through evaluation and the cancer drugs fund
- Outlook – HTA decisions in Germany, the UK and France in comparison

16h15

Value assessment and pricing – other mechanisms in Europe

Dr Alexander Natz

17h00 Conference end

Registration under
service@forum-institut.com or
Fax +49 6221 500-555

Registration Form

Yes, I will attend the international meeting

☐ Value Assessment & Pricing in France,
the UK and Germany

☐ I am interested in receiving more information on FORUM
events and agree that this information be sent to me by e-mail.

Name _____

Position/Department _____

Company _____

Street _____

Postal Code/City/Country _____

Tel. No. _____

E-Mail _____

Contact person at office _____

Date, Signature _____

How to register

Registration: +49 6221 500-500

Conference-No. 15 09 234

Internet:

www.forum-institut.com

Date/Venue:

Thursday, 24 September 2015 in Berlin
8h30 registration; 9h00 - 17h00 conference
Hotel Palace
Budapester Str. 45 · 10787 Berlin
Tel. +49 30 2502-1190 · Fax +49 30 2502-1199

Fee:

€ 1,090.- (+ German VAT)

The fee includes course documentation (incl. free
download) as well as midsession refreshments,
lunch and certificate. Invoice and confirmation will
be forwarded to you.

Hotel accommodation:

A limited number of rooms have been reserved at
the hotel and are subject to availability. Please book
at least six weeks prior to the seminar to obtain
a hotel room at the discounted rate. All bookings
should be made directly with the hotel quoting
Forum-Institut and the Seminar-No.

Any further questions?



I am gladly at your disposal
should you have any further
questions about the meeting.

Dr. Henriette Wolf-Klein
Department Manager
Tel. +49 6221 500-680
h.wolf-klein@forum-institut.de

Cancellation Policy

Our general terms and conditions apply (as of
1 December 2011) and are available upon request.
We can send them to you anytime or you can find them on
the internet at www.forum-institut.de/agb_en